At the Virginia Institute for Psychiatric and Behavioral Genetics, consistent with the School of Medicine Diversity, Equity, and Inclusion statement, we strive to conduct innovative, ethical research of the highest quality across diverse populations, while fostering an inclusive, collaborative, and unprejudiced1,2 environment in which to educate the next generation of scientists. Accordingly, we, the members of VIPBG, endeavor to create and nurture an environment where all voices are heard. Inclusivity, diversity, equity, and access across personal, scientific, and organizational domains are valued and promoted. These efforts are ongoing and active, requiring continual self-reflection, dialogue, evaluation, and improvement.
Diversity encompasses all aspects of race, ethnicity, gender, gender identity, age, sexual orientation, ability, socio-economic status, religious beliefs, geographic region, nationality, language, political beliefs, ideas, and values. Collaborative groups who embrace inclusivity benefit from varied perspectives. Indeed, having diversity within a team increases the likelihood of generating prolific, innovative, and impactful scientific output3,4,5.
We recognize and condemn the practice of eugenics and the historical misuse of psychiatric and behavioral genetics research to justify racist and ableist policies and atrocities. Our educational mission includes reflecting on this past and implementing equitable and just paths forward. As researchers we strive to achieve parity by including diverse samples, and by developing and applying methods to best understand and improve population health for all.
IDEA-Related Funding Opportunities
id
Sponsor
Identifier
Title
Expires
Link
Summary
1
NIH
NOT-OD-22-178
Notice of Special Interest (NOSI): Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan
2025-05-08
The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved.
2
NIH
NOT-MD-22-012
Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations
2025-08-08
This Notice is a reissue of and supersedes NOT-MD-19-001 - Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations which calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex.
3
NIH
PA-21-071
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
2023-05-08
The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project.
4
NIH
RFA-MH-22-140
Understanding Suicide Risk and Protective Factors among Black Youth (R01 Clinical Trial Not Allowed)
2023-06-21
This Funding Opportunity Announcement (FOA) aims to advance translational research to better understand factors that confer risk and resilience for suicide among Black youth.
5
NIH
RFA-MH-22-141
Understanding Suicide Risk and Protective Factors among Black Youth (R01 Clinical Trial Not Allowed)
2023-06-21
This Funding Opportunity Announcement (FOA) aims to advance translational research to better understand factors that confer risk and resilience for suicide among Black youth.
6
NIH
RFA-HG-22-004
Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed)
2023-07-02
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NHGRI R25 program is to support educational activities that encourage undergraduates from diverse backgrounds, including those from groups underrepresented in the biomedical workforce, to pursue further training and careers in the scientific, medical, ethical, social and/or legal areas of genomics research.
7
NIH
PA-21-052
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
2023-09-08
The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce.
8
NIH
PAR-20-179
Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)
2023-09-08
This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity.
9
NIH
PAR-20-236
Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed)
2023-11-16
The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
10
NIH
PAR-21-277
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)
2023-11-16
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIH MOSAIC UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
11
NIH
RFA-NS-21-012
NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Clinical Trial Not Allowed)
2023-12-16
The purpose of the NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences.
12
NIH
RFA-EY-21-003
BRAIN Initiative-Related Research Education: Short Courses (R25 Clinical Trial Not Allowed)
2024-02-16
The purpose of this FOA is to encourage applications for the continuation of ongoing and creation of new courses for skills development that will significantly advance the educational goals of the BRAIN Initiative as described in The BRAIN Initiative®2.0: From Cells to Circuits, Toward Cures including neuroethics and opportunities to increase the workforce diversity in BRAIN Initiative research areas.
13
NIH
RFA-HG-21-041
New Investigators to Promote Workforce Diversity in Genomics, Bioinformatics, or Bioengineering and Biomedical Imaging Research (R01 Clinical Trial Optional)
2024-02-23
This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Human Genome Research Institute (NHGRI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), and All of Us Research Program (All of Us). This program is intended to support Early Stage Investigators and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.
14
NIH
PAR-22-072
Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01 Clinical Trial Not Allowed)
2024-05-08
The purpose of this Funding Opportunity Announcement (FOA) is to support research that will advance the measurement and methodology of complex constructs relevant to minority health and health disparities.
15
NIH
PAR-21-325
Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed)
2024-09-08
The purpose of this Funding Opportunity Announcement (FOA) is to enhance the diversity of the mental health research workforce by providing dissertation awards in all research areas within the strategic priorities of the NIMH to individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research. This FOA provides support to complete a mental health-related doctoral research project and includes funds not readily available in NRSA predoctoral (F31) awards, which limit support to stipends, tuition and fees, and institutional allowance.
16
NIH
PAR-21-271
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
2024-09-08
The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas.
17
NIH
PAR-21-273
Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Basic Experimental Studies with Humans Required (BESH))
2024-09-08
The purpose of the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of early career, independent investigators from diverse backgrounds conducting research in NIH mission areas.
18
NIH
PAR-21-313
Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)
2024-09-08
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI).
19
NIH
PAR-22-097
Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
2024-12-10
This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system function and disorders throughout life, relevant to LMICs.
20
NIH
PAR-22-098
Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
2024-12-10
This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, piloting innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system-related function and disorders throughout life, relevant to LMICs.
21
NIH
NOT-MH-22-045
Notice of Special Interest (NOSI): Secondary Analysis of Posttraumatic Psychopathology Data
2025-01-08
NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to analyze existing and accumulating data to aid in refining phenotypes of posttraumatic psychopathology(ies), markers of onset and change, and risk detection. NIMH is also interested in research using available data to identify potential prevention and treatment targets and to advance and refine measurement and validation of potential novel targets for future development in experimental therapeutics research.
22
NIH
RFA-DA-23-026
NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio.. This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders.
23
NIH
RFA-DA-23-031
NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio.. This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders.
24
NIH
RFA-DA-23-013
NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities insubstance use, addiction, and related health consequences, including HIV. Applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities.
25
NIH
RFA-DA-23-032
NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities insubstance use, addiction, and related health consequences, including HIV. Applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities.
26
NIH
RFA-DA-23-053
HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
2024-03-21
There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels.
27
NIH
RFA-DA-23-054
HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
2024-03-21
There remains an urgent need for research that advances the design of stigma-free patient-centered systems of care such that people who experience addiction can recover and sustain their recovery over the long-term. This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels.
28
NIH
RFA-DA-23-023
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional)
2024-11-15
The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
29
NIH
RFA-DA-23-024
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional)
2024-11-15
The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
30
NIH
RFA-DA-23-028
NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.
31
NIH
RFA-DA-23-029
NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
2024-11-15
This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.
32
NIH
RFA-MH-22-185
NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
2025-06-21
The NIMH Biobehavioral Research Awards for Innovative New Scientists (BRAINS) award is intended to support the research and research career advancement of outstanding, exceptionally productive scientists who are in the early, formative stages of their careers and who plan to make a long-term career commitment to research in specific mission areas of the NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, basic, or services research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders.
33
NIH
RFA-HG-22-026
Diversity Centers for Genome Research (U54 Clinical Trials Optional)
2024-06-24
The Diversity Center for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. Each DCGR award will support a multi-investigator, interdisciplinary team to develop 2-3 interrelated, innovative genomic research projects. Each project should address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics; ethical, legal, and social implications of genomic research; and/or genomics and health equity.
34
NIH
RFA-HG-22-027
Diversity Centers for Genome Research (UG3/UH3 Clinical Trials Optional)
2024-06-24
The full-scale Diversity Centers for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. The purpose of this FOA is to call for applications for UG3/UH3 cooperative agreements to support the development and planning for a multi-investigator, interdisciplinary team to develop administrative, genomic workforce development and community engagement cores and 2-3 interrelated, innovative genomic research projects.
35
NIH
PAR-23-030
Leading Equity and Diversity in the Medical Scientist Training Program (LEAD MSTP)(T32)
2025-01-27
The goal of the Leading Equity and Diversity in the Medical Scientist Training Program (LEAD MSTP) is to develop a diverse pool of highly trained clinician-scientist leaders available to meet the Nation’s biomedical research needs by providing support for dual-degree clinician scientist training at institutions that have historically not been well represented among NIGMS-funded MSTPs.
36
NIH
NOT-OD-23-002
Notice of Special Interest (NOSI): Administrative Supplements to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility (DEIA) Mentorship
-0001-11-30
The participating Institutes and Centers (ICs) are inviting applications to support administrative supplements to existing NIH awards to support scientists who have demonstrated compelling commitments and contributions to mentorship and enhancing diversity, equity, inclusion, and accessibility (DEIA) in the biomedical sciences.
37
NIH
PAR-23-037
Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
2026-05-07
The purpose of this funding opportunity announcement (FOA) is to invite applications for multisite clinical trials and observational studies that will be conducted using NICHD-supported network infrastructure. One of the goals of this FOA is to facilitate greater involvement of diverse populations in multisite studies.
38
NIH
RFA-DA-23-062
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional)
2024-11-14
The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
39
NIH
RFA-DA-23-061
NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional)
2024-11-14
The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.
40
NIH
PAR-23-068
Limited Competition: Brain Tissue Resource Center for Alcohol Research (R28 Clinical Trial Not Allowed)
2023-03-14
The purpose of this limited competition FOA is to encourage a resource project (R28) application from a center currently supported under an existing grant, entitled “Brain Tissue Resource Center for Alcohol Research” to (i) develop a “bank” of brain tissues (fresh-frozen and formalin-fixed) from People with Alcohol Use Disorder (AUD) and control cases with confirmed clinical and pathological diagnoses, (ii) develop and promote a prospective brain donor program in Australia (“Using our Brains”) to enhance the “brain bank”, (iii) establish an associated DNA (blood) bank from the brain donor group, and (iv) invite research groups with an interest in alcohol-related brain damage to submit applications for studies using these tissues.
41
NIH
PAR-23-075
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
2026-01-07
The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects.
42
NIH
RFA-DA-24-014
Mechanisms and Targets at the Intersection of HIV and Substance Use (R21 Clinical Trials Not Allowed)
2023-08-09
The purpose of this Funding Opportunity Announcement (FOA) is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications, which are commonly affected by HIV and substance use and lead to neuropathology and neurocognitive dysfunction.
43
NIH
RFA-DA-24-013
Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed)
2023-08-09
Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.
44
NIH
NOT-DA-23-013
Notice of Special Interest (NOSI): Research to Address Ending the HIV Epidemic Initiative Goals Relevant to Substance Using Populations At-Risk for or Living with HIV
-0001-11-30
The purpose of this Funding Opportunity Announcement (FOA) is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. NIDA is specifically interested in supporting basic research on signaling pathways, virus-host protein interactions, and post-translational protein modifications, which are commonly affected by HIV and substance use and lead to neuropathology and neurocognitive dysfunction.
45
NIH
PAR-23-076
NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
2025-11-18
This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA’s mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. It is expected that a Center will transform the scientific fields of focus. New and creative directions, but not incremental work, should be the focus of Center activities. The P50 Center of Excellence is expected to mentor and foster the career development of new and early career investigators by providing meaningful roles in the Center projects and research activities. The overarching goal of this program is to create NIDA Centers that will serve as the national resources to advance research relevant to substance use and SUDs by facilitating collaborations, sharing of data, research tools and reagents.
46
NIH
PAR-23-049
NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
2025-11-17
NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance and extend existing research relevant to substance use/misuse and addiction and HIV. Centers are expected to transform the scientific field of study by facilitating research, providing administrative support and a rigorous research climate that promotes new and creative directions. Incremental work should not be the focus of Center activities. Applications responding to this Funding Opportunity Announcement (FOA) are strongly encouraged to integrate and promote research in the funded projects and support interdisciplinary collaborations.Centers also must focus on providing research opportunities and experiences to new and early career investigators from diverse backgrounds, including those from underrepresented populations or institutions, facilitating collaborations, and linking and sharing data, research findings and resources to achieve the goals of the program.
47
NIH
RFA-DA-24-010
Rapid Translation of Epidemiological Findings into Interventions to Prevent Substance Use and Addiction (R61/R33 Clinical Trial Optional)
2023-03-15
This Funding Opportunity Announcement (FOA) supports research led by multidisciplinary teams to advance translation of epidemiological research into interventions to prevent substance use and addiction. The R61/R33 Phased Innovation Award mechanism is used to support exploratory/developmental research with the potential for high impact. Applications are required to use a Multiple-Principal Investigator (MPI) structure and clearly demonstrate how epidemiological findings from the R61 phase will inform intervention research in the R33 phase.
48
NIH
NOT-MH-23-140
Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services
-0001-11-30
The National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), and Office of Research on Women’s Health (ORWH) are issuing this Notice of Special Interest (NOSI) to outline priorities for research in crisis response services. Research is sought that is conducted in real-world settings, where a wide range of clinical presentations, psychosocial factors, age-related (e.g., youth; adult; older adult), geographic (rural/remote settings), cultural considerations, and health disparities influence the types of care that are provided. Studies are encouraged that address the continuum of crisis service systems, as well as applications that address crisis services for children and under-resourced populations.
49
NIH
PAR-23-050
Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
2026-01-07
This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase the inclusion of women and minorities (NOT-OD-18-014) and NIH-defined health disparity populations. (see https://www.nimhd.nih.gov/about/strategic-plan/nih-strategic-plan-definitions-and-parameters.html). It is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.
50
NIH
PAR-23-087
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
2025-06-20
The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate goal of this FOA is to improve the efficiency of the therapeutic development process by identifying congruent measures as well as inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates.
51
NIH
PAR-23-092
Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)
2024-07-05
This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span.
52
NIH
RFA-MH-23-116
Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional)
2023-03-24
Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental health and risk for psychopathology. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity RFA-MH-23-115 seeks R01 grant applications proposing longer term projects with supporting preliminary data.
53
NIH
RFA-MH-23-115
Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional)
2023-03-24
Adolescents have increasing access to and spend an increasing amount of time engaging in online social interactions and consuming content on social media platforms, yet there is limited knowledge of how online social behavior and experiences interact with adolescent mental health and risk for psychopathology. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that focus on understanding bidirectional relationships between social media use and adolescent mental health, psychiatric symptoms, and risk or resilience for psychopathology. This FOA uses the R01 grant mechanism, whereas its companion FOA, RFA-MH-23-116, seeks shorter, higher-risk R21 grant applications.
54
NIH
NOT-MD-23-001
Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience Pilot Research Projects at NIMHD-Funded Research Centers in Minority Institutions (RCMI)
-0001-11-30
This Notice of Special Interest (NOSI) invites applications for administrative supplements to NIMHD Research Centers in Minority Institutions (RCMI) U54 awards to support pilot research projects led by early-stage investigators (ESIs) and new investigators (NIs) focused on research on substance use, addiction, and/or neuroscience, as a bridge to independently funded careers. It is expected that pilot project PIs will work with their institutions to prepare and submit follow-up research grant or career development applications to NIH based on the research supported by these supplemental funds.
55
NIH
NOT-DA-24-001
Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine.
-0001-11-30
Variable responses to ART are due at least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site drug targets. Defining effects of human genetic variants on HIV treatment toxicity, efficacy, and pharmacokinetics has far-reaching implications. Substances of abuse (opioid, stimulants, nicotine, anxiolytics, alcohol, etc.) and its treatments (methadone, buprenorphine, extended naltrexone, etc.) may interact with ART, altering its bioavailability, its safety, and its efficacy. It is known that nevirapine and efavirenz increase methadone clearance. New evidence demonstrates that variabilities in responses to ART depend in part on genetic variants for certain drugs of abuse and its therapies. For instance, a NR1I3 gene variant affected methadone clearance only in those taking efavirenz. Two other genetic variants in the ABCB1 and CYP2B6 genes decreased methadone clearance. More research, though, is necessary to better understand the role of pharmacogenomics in people with HIV (PLWH) with substance use disorders (SUD).
56
NIH
NOT-GM-23-028
Notice of Special Interest (NOSI) in Applications to Support Training, Workforce Development, and Diversity Conferences (R13)
-0001-11-30
This Notice of Special Interest (NOSI) encourages applications for support of conferences focused on evidence-informed interventions to enhance training, workforce development and diversity in the biomedical research enterprise.
57
NIH
RFA-DA-24-037
Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
2024-11-15
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.
58
NIH
RFA-MD-23-008
Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)
2023-04-03
The objective of this initiative is to further knowledge about how to best reduce the number of new HIV infections in the US through interventions to promote pre-exposure prophylaxis (PrEP), condom use, and HIV testing. This initiative will support research projects that test the effectiveness of multi-level interventions to prevent HIV in high-risk health disparity populations or subgroups in one or more geographic areas with a high rate of new HIV infections.